Dow Up0.07% Nasdaq Up0.61%

More On COT.V

Quotes

Charts

News & Info

Company

Analyst Coverage

Ownership

  • Major Holders
  • Insider Transactions
  • Insider Roster

Financials


Critical Outcome Technologies Inc. (COT.V)

-TSXV
0.26 0.00(0.00%) 10:41AM EST
ProfileGet Profile for:
Critical Outcome Technologies Inc.
The Stiller Centre
Suite 213
London, ON N6G 4X8
Canada - Map
Phone: 519-858-5157
Fax: 519-858-5179
Website: http://www.criticaloutcome.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:6

Business Summary 

Critical Outcome Technologies Inc., a bioinformatics company, is engaged in the discovery and development of small molecules. The company focuses on applying CHEMSAS, a proprietary computer based technology, which identifies, profiles, optimizes, selects, and validates commercially viable drug candidates at the discovery stage of preclinical drug development. It focuses on developing drug candidates for the treatment of various cancers, such as acute myelogenous leukemia, small cell lung, ovarian, endometrial, pancreatic, brain, breast, and colorectal cancers, as well as HIV, multiple sclerosis, Alzheimer’s disease, and methicillin-resistant staphylococcus aureus. Its lead oncology compound is COTI-2, a molecule in Phase I clinical trial. The company is also engaged in the development of Rosalind, which provides personalized oncology drug treatment recommendations to physicians and patients based on the genetic profile of each individual patient’s specific cancer. Critical Outcome Technologies Inc. is headquartered in London, Canada.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Critical Outcome Technologies Inc.

Key Executives 
 PayExercised
Mr. John C. Drake LLB, 66
Exec. Chairman, Sr. Advisor and Member of The Bus. Advisory Board
N/AN/A
Dr. Wayne R. Danter M.D., FRCPC,
Co-Founder, Chief Exec. Officer, Pres, Chief Scientific Officer, Non-Independent Director and Chairman of Scientific Advisory Committee
N/AN/A
Dr. Kathleen A. Ferguson M.D., FRCPC,
Co-Founder, Treasurer, Sec. and Member of Compensation Committee
N/AN/A
Mr. Eugene Francis Kelly ,
Chief Financial Officer
N/AN/A
Mr. Michael Barr ,
VP of Marketing and Bus. Devel.
N/AN/A
Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in CAD.